I cited and linked this page in my post. (I wish people would pay attention!)
For those who choose not to do so, my point was that they knew at that time that Medicare has approved G6, but described that approval as something that would happen in the future. They decided this “tweak” was necessary to simultaneously keep customers interested while suppressing the cause of the delay being the production facility.
Suppressing causal information is a bad habit with potentially serious consequences for the company doing so.
A more dramatic example is when, several years back, Muro 128 Ocular Gel had a crystallization problem caused by insufficient insulation in the shipping vehicles during the winter. These crystal caused eye damage to the cornea and elsewhere, such as scars that cannot be corrected and if serious enough can require corneal transplant. The problem was that the manufacturer (Bausch & Lomb) did not disclose this (neither to patients OR doctors), rather categorizing the problem as a “Voluntary Recall” that requires a user to have the symptoms and going to an ophthalmologist to determine what is wrong, which then causes the physician new to the issue to solve the puzzle. Even if the physician is aware of this, it can too late for the patient.
To me, Dexcom withholding the actual cause of the Medicare delay (i.e., their decision in how to handle the production/shipping problem) is the same unethical behavior. Also, keep in mind that DME manufacturers, being in the healthcare space, may well be obliged to abide by HIPAA and HIPAA 2 regulations, in which patients are defined as “interested parties” (along with doctors, et al), and so may incur some difficulties.
While the G6 issue is far less serious than the Muro problem, it is marching to the same beat.